Published Guideline
READ GUIDELINE
"Society for Immunotherapy of Cancer (SITC) clinical practice guideline on immunotherapy for the treatment of hepatocellular carcinoma" originally published The Journal for ImmunoTherapy of Cancer (JITC) on September 12, 2021.
Updated Content (last reviewed 5/3/24)
SITC continually monitors for practice-changing data and new FDA approvals that may affect the guideline. The information on this page provides a detailed overview of updates to the guideline content based on changes in the field. Updates to the guideline outlined below were made with the approval of SITC's HCC CPG Expert Panel. More information on SITC Guidelines can be found here.
v1.1(A) Update Summary
On October 21, 2022, the United States Food and Drug Administration approved tremelimumab in combination with durvalumab for adult patients with unresectable HCC. Approval was based on statistically significant and clinically meaningful improvement in overall survival for tremelimumab plus durvalumab compared to sorafenib in the phase III HIMALAYA trial, which enrolled patients with confirmed unresectable HCC who had not received prior systemic treatment. In light of this approval, narrative text and recommendations within the guideline were updated via an addendum. Additionally, a new treatment algorithm was developed.